Universitetssjukhuset i Linköping

Linköping, Östergötlands Län [se-05] 581 85

1 studies enrolling now · 2 studies all time

What they study most

Breast Neoplasms, Multiple Myeloma

Studies at this site

• A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) — Recruiting now
• Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant — Running, not enrolling